University of Pennsylvania School of Medicine scientists have developed a high-throughput functional cell-based screen using bioluminescence imaging to identify small molecules that modulate p53 transcriptional activity or p53-related proteins in cancer cells, and exhibit anti-cancer activity in human colon cancer xenografts.

The study underscores the importance of p53-related pathways and downstream molecules as potential drug targets, and could help establish bioluminescent cell-based assays as an effective way to screen modulators of such targets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.